KB-1174

Cusatuzumab

52666

Home » Cusatuzumab

Background of Cusatuzumab

CD70, a tumor necrosis factor receptor ligand, is a very promising target due to its consistent expression on LSC and AML blasts. In AML, the binding of CD70 to its receptor, CD27, on LSC and subsequent downstream signaling activates gene-expression profiles that promote LSC proliferation, reduce differentiation, and lead to release of soluble CD27. Cusatuzumab (ARGX-110) is a high-affinity, anti-CD70 monoclonal antibody that blocks CD70/CD27 signaling, leading to inhibition of LSC proliferation, a reduction in leukemic blast cells, blockade of regulatory T-cell survival (preventing tumor immune escape), and restoration of normal myeloid differentiation.

Specifications

Catalog Number	KB-1174
Antibody Name	Cusatuzumab
Isotype	Human IgG1, kappa
FC Muations	Wild Type
Target	CD70
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Riether C, Schürch CM, Bührer ED, et al.. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017;214(2):359-380.
Silence K, Dreier T, Moshir M, et al.. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade. MAbs. 2014;6(2):523-532.